Meet The Team

The Founders

Anath Shalev, Founder

Anath Shalev, MD
Founder, Chief Scientific Officer, Chief Medical Officer, and Board Member

Professor of Medicine
Director, Comprehensive  Diabetes Center
Nancy R. and Eugene C. Gwaltney Family Endowed Chair in Juvenile Diabetes Research
University of Alabama at Birmingham

A headshot of Mike Goodrich

T. Michael Goodrich, II, JD
President, Executive Board Chair, and General Counsel

Manager
First Avenue Ventures Life Science, LLC
Birmingham, Alabama

Business Development expert Stephen Daly.

Stephen Daly
Chief Executive Officer, Chief Financial Officer, and Board Member

30+ years of experience in commercialization and product development, including 20 years in diabetes and metabolism. 
BS in Business Administration from Northeastern University (Finance and Information Systems) and MBA studies at the University of Florida (Decision Science).
Held executive leadership positions at companies in the metabolism field including Modular Medical, Adocia, Halozyme, Amylin Pharmaceuticals, and Abvance Therapeutics. 
Previously consulted on Vertex’s T1D islet cell program (VX-264).
Amylin and Adocia logos.
Abvance Therapeutics logo.

The Scientific Advisory Board

G. Alexander Fleming

David M. Harlan, MD
Chair, Scientific Advisory Board & Executive Board Member

William and Doris Krupp Professor of Medicine
Director, UMass Diabetes Center of Excellence
Umass Memorial Health
Umass Chan Medical School

Brian Oscherwitz

Alan Moses, MD
Member, Scientific Advisory Board

Consultant
Senior Vice President and Chief Medical Officer of Joslin Diabetes Center (-2004)
Senior Vice President and Global Chief Medical Officer of Novo Nordisk (-2018)

Thomas Seoh, J.D.

C. Ronald Kahn, MD
Member, Scientific Advisory Board

Mary K. Iacocca Professor of Medicine, Harvard Medical School
Chief Academic Officer, Joslin Diabetes Center

Extended Team of Experts

Daniel Bradbury

Al Collinson, PhD
Board Member

Daniel Bradbury

Daniel Bradbury
Strategic Advisor

G. Alexander Fleming

G. Alexander Fleming, MD
Strategic Regulatory & Clinical Development Expert

Brian Oscherwitz

Brian Oscherwitz, MBA, PMP
Operational Oversight

G. Alexander Fleming

Jo Van Betsbrugge, PhD
Chemistry, Manufacturing & Controls (CMC)

Shana Azri Meehan

Shana Azri-Meehan, PhD, DABT
Toxicology

Thomas Seoh, J.D.

Michael B. Zemel, PhD
Translational, Clinical & Regulatory Expert

TIXiMED Logo

Kinexum’s Drs. Fleming, Oscherwitz, Betsbrugge, Azri-Meehan, and Zemel have decades of experience helping guide life science companies in the diabetes and metabolism field in the design and implementation of FDA regulatory,  manufacturing, nonclinical and clinical drug development and business efforts, and are now working with TIXiMED.